Gallbladder and bile duct cancers: Rare, silent and deadly. Know the signs

by Cara MurezBile duct and gallbladder cancers develop in organs deep inside the body, making them difficult to detect.Knowing the signs of these rare cancers may help with earlier detection.Gallbladd

Updated on: December 20,2023

Gallbladder and bile duct cancers: Rare, silent and deadly. Know the signs

by Cara MurezBile duct and gallbladder cancers develop in organs deep inside the body, making them difficult to detect.Knowing the signs of these rare cancers may help with earlier detection.Gallbladd

Updated on:December 20,2023

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on: September 15,2024

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on:September 15,2024

Multicancer early detection feasible for outpatients

A blood-based multicancer early detection (MCED) test using cell-free DNA (cfDNA) is feasible for outpatients and has a positive predictive value of about 40 percent, according to a study presented at

Updated on: December 21,2023

Multicancer early detection feasible for outpatients

A blood-based multicancer early detection (MCED) test using cell-free DNA (cfDNA) is feasible for outpatients and has a positive predictive value of about 40 percent, according to a study presented at

Updated on:December 21,2023

Frailty score may predict outcomes in multiple myeloma

(HealthDay)—A frailty scale that includes Eastern Cooperative Oncology Group performance status (ECOG PS) may predict outcomes for transplant-ineligible patients with newly diagnosed multiple myeloma

Updated on: December 20,2023

Frailty score may predict outcomes in multiple myeloma

(HealthDay)—A frailty scale that includes Eastern Cooperative Oncology Group performance status (ECOG PS) may predict outcomes for transplant-ineligible patients with newly diagnosed multiple myeloma

Updated on:December 20,2023

New insights into the drivers of glioma-related epilepsy

by Graciela Gutierrez,Baylor College of MedicineGraphical abstract. Credit:Neuron(2023). DOI: 10.1016/j.neuron.2023.01.013Glioma is one of the most aggressive malignant primary brain

Updated on: December 20,2023

New insights into the drivers of glioma-related epilepsy

by Graciela Gutierrez,Baylor College of MedicineGraphical abstract. Credit:Neuron(2023). DOI: 10.1016/j.neuron.2023.01.013Glioma is one of the most aggressive malignant primary brain

Updated on:December 20,2023

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell

Updated on: October 27,2023

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell

Updated on:October 27,2023

Why some cancers affect only young women

byUniversity of GenevaCredit: CC0 Public DomainAmong several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an

Updated on: December 18,2023

Why some cancers affect only young women

byUniversity of GenevaCredit: CC0 Public DomainAmong several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an

Updated on:December 18,2023

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) t

Updated on: December 17,2023

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) t

Updated on:December 17,2023

Allogeneic HCT after primary induction failure beneficial in leukemia

by Elana GotkineFor patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term survival benef

Updated on: December 26,2023

Allogeneic HCT after primary induction failure beneficial in leukemia

by Elana GotkineFor patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term survival benef

Updated on:December 26,2023

Squamous cell carcinoma study: Cancer stem cells are fueled through dialogue with their

Squamous cell carcinoma study: Cancer stem cells are fueled through dialogue with their environmentsbyRockefeller UniversityTGF beta signaling (red) is one way that the environment causes cancer

Updated on: October 29,2023

Squamous cell carcinoma study: Cancer stem cells are fueled through dialogue with their

Squamous cell carcinoma study: Cancer stem cells are fueled through dialogue with their environmentsbyRockefeller UniversityTGF beta signaling (red) is one way that the environment causes cancer

Updated on:October 29,2023

Targeting epiregulin in treatment-damaged tumor microenvironment restrains therapeutic resistance

by Liu Jia,Chinese Academy of SciencesGenotoxicity induces expression of EREG and other secreted factors of the SASP spectrum in human stromal cells.aTranscriptome-wide profiling of

Updated on: December 19,2023

Targeting epiregulin in treatment-damaged tumor microenvironment restrains therapeutic resistance

by Liu Jia,Chinese Academy of SciencesGenotoxicity induces expression of EREG and other secreted factors of the SASP spectrum in human stromal cells.aTranscriptome-wide profiling of

Updated on:December 19,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on: October 12,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on:October 12,2023